CTMX
CytomX Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$875.52M
P/E Ratio
—
EPS
$-0.15
Beta
2.48
52W High
$8.21
52W Low
$0.76
50-Day MA
$4.79
200-Day MA
$3.82
Dividend Yield
—
Profit Margin
-22.80%
Forward P/E
7.43
PEG Ratio
-1.80
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | $76.20M |
| Gross Profit (TTM) | $76.20M |
| EBITDA | $-18.19M |
| Operating Margin | -3791.00% |
| Return on Equity | -35.20% |
| Return on Assets | -8.99% |
| Revenue/Share (TTM) | $0.55 |
| Book Value | $0.58 |
| Price-to-Book | 8.84 |
| Price-to-Sales (TTM) | 11.49 |
| EV/Revenue | 9.75 |
| EV/EBITDA | 24.67 |
| Quarterly Earnings Growth (YoY) | 60.60% |
| Quarterly Revenue Growth (YoY) | -98.30% |
| Shares Outstanding | $216.18M |
| Float | $148.11M |
| % Insiders | 0.66% |
| % Institutions | 75.88% |
Historical Volatility
HV 10-Day
51.81%
HV 20-Day
44.76%
HV 30-Day
83.87%
HV 60-Day
115.96%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($13.67 target)
3
Strong Buy6
BuyData last updated: 4/30/2026